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 In search of a better 
understanding of IgA 
nephropathy-associated 
hematuria 
 Frank  Eitner 1 , 2 and  J ü rgen  Floege 1 
 Although microscopic or episodic macroscopic hematuria is the key 
clinical manifestation of IgA nephropathy (IgAN), still very little is known 
about its pathogenesis. Cox  et al. studied IgAN patients during episodes 
of macroscopic hematuria and identified an upregulated expression of 
the chemokine receptor CX3CR1 in their circulating leukocytes. On the 
basis of a series of additional experimental approaches, they suggest 
that CX3CR1 and its ligand fractalkine may contribute to the onset of 
macroscopic hematuria in IgAN. 
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 Th e most consistent clinical manifestation 
of IgA nephropathy (IgAN) is the presence 
of hematuria. 1 Clinically, hematuria distin-
guishes two forms of IgAN: up to half of the 
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patients present with episodes of macro-
scopic hematuria, whereas asymptomatic 
microscopic hematuria is the presentation 
in the other half in most reported series. 
Episodes of macrohematuria usually follow 
mucosal infections, commonly in the upper 
respiratory tract or occasionally in the gas-
trointestinal tract, but can also coincide 
with physical exercise. 1,2 In particular, in 
adult IgAN patients, macrohematuria oft en 
precipitates acute kidney injury, and up to 
a quarter of these patients, especially elderly 
patients with prior impairment of the 
glomerular fi ltration rate, do not recover 
completely. 3 
 Does the hematuria pattern separate 
two IgA nephropathy disease entities? 
 During follow-up, episodes of macro-
hematuria are very rare in IgAN patients 
who initially present with asymptomatic 
micro hematuria, yet very frequent in 
patients who initially present with macro-
hematuria. Th is observation has been used 
as an argument that the two hematuria 
patterns separate two distinct disease 
entities. 4 Alternatively, hematuria patterns 
might simply relate to the age at which the 
disease fi rst manifests. Indeed, recurrent 
macrohematuria is the defi ning clinical 
feature in 80 – 90 % of all pediatric IgAN 
patients and is very rarely a presenting 
manifestation aft er the age of 40 years. 1 
 Recurrent macrohematuria has also 
been analyzed for its value as a clinical 
indicator of disease progression. 1 In con-
trast to proteinuria, arterial hypertension, 
and an impaired glomerular fi ltration rate, 
all of which strongly predict a negative 
outcome, a history of recurrent macro-
hematuria appeared to predict a better 
prognosis in IgAN. 1 However, given the 
signifi cantly younger age of patients with 
recurrent macrohematuria, this might 
represent lead-time bias, as such patients 
might simply have had a shorter disease 
duration. Consequently, current IgAN 
treatment suggestions are based on 
glomerular fi ltration rate and degree of 
proteinuria and not on the presence or 
degree of hematuria. 5 
 Studying IgA nephropathy patients 
at the time of overt macroscopic 
hematuria might help in understanding 
disease pathogenesis 
 Remarkably little is known about the 
mole cular mechanisms that cause persist-
ent microscopic or episodic macroscopic 
hema turia in IgAN, and more insight into 
these pathomechanisms might trans late 
into a better understanding of IgAN dis-
ease initiation and progression. 
 In an elegant series of experiments, the 
group of Cox  et al. 6 (this issue) focused on 
macrohematuric IgAN patients. Periph-
eral blood mononuclear cells (PBMCs) 
were isolated from patients during an epi-
sode of macroscopic hematuria and later 
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during remission with persistent micro-
scopic hematuria. With the use of a variety 
of techniques, the chemokine receptor 
CX3CR1 was found upregulated at the 
time of macroscopic hematuria but not in 
microscopic hematuria on natural killer 
cells, natural killer T cells, CD8  +  cells, and 
  /  -T cells.  In vitro , PBMCs obtained from 
IgAN patients, but not those with mem-
branous or membranoproliferative 
glomerulonephritis, responded to lipopol-
ysaccharide with enhanced CX3CR1 
expression, suggesting an endogenous 
predisposition of IgAN PBMCs to express 
this chemokine receptor. Notably, at least 
 in vitro this response was similar in 
PBMCs obtained from patients with 
recurrent macrohematuria and those 
without, suggesting that upregulated 
CX3CR1 alone is not suffi  cient to explain 
the diff erent hematuria patterns. Finally, 
increases in the corresponding chemokine 
ligand CX3CL1 (fractalkine) were detected 
in renal biopsies and in the urine of IgAN 
patients with a history of recurrent mac-
roscopic hematuria episodes. 6 Th e authors 
conclude that the CX3CR1 – fractalkine 
axis may contribute to the pathogenesis of 
macrohematuria in IgAN. 
 How do these novel fi ndings fi t into our 
current concept of IgA nephropathy 
pathogenesis? 
 Th e fi ndings of Cox  et al. 6 off er novel 
in sights in our understanding of IgAN 
pathogenesis by adding upregulated 
CX3CR1-positive cytotoxic eff ector 
lymphocytes to the list of immune pheno-
mena present in IgAN patients. 
 The humoral component of IgAN 
appears to involve elevated poorly galac-
tosylated IgA 1  O -glycoforms, both in the 
circulation and in glomerular deposits. 2,7 
The exact mechanisms that trigger the 
overproduction of poorly galactosylated 
IgA 1 remain unknown. It has been hypoth-
esized that the homing of lymphocytes 
between mucosal and systemic sites is 
altered in IgAN patients, resulting in a 
misdirection of mucosal plasma cells to 
systemic sites that secrete their  ‘ correct, ’ 
poorly galactosylated, mucosal-type IgA 1 
into the circulation. 8 Factors controlling 
the diff erential  N -linked and  O -linked gly-
cosylation of mucosal IgA are not known. 
 CX3CR1 is a key chemokine receptor 
involved in mucosal function. Thus, 
CX3CR1 is associated with the mainte-
nance of intestinal macrophage populations 
that prevent translocation of bacteria 
to mesenteric lymph nodes and limit coli-
togenic Th 17 responses. 9 Whereas macro-
phages and dendritic cells were not 
investigated in the study of Cox  et al. , 6 they 
found increased expression of CX3CR1 on 
circulating T-cell populations, including 
the   /  -T cells. Th is T-cell population plays 
a role in regulating mucosal IgA produc-
tion and oral tolerance. 7 A selective defi -
ciency of a   /  -T-cell subset has been 
reported in the duodenal mucosa of 
patients with IgAN. 7 How this relates to 
macrohematuria episodes, and whether 
this phenomenon is specifi c to IgAN, are 
currently unknown. Possibly, however, it 
could indicate altered homing of   /  -T cells 
in these patients, that is, fi t to a misdirected 
homing of mucosal lymphocytes in 
the pathogenesis of IgAN that leads to 
an altered CX3CR1-expressing PBMC 
population. 
 Finally, both CX3CR1 and fractalkine 
are known players in the induction of 
local infl ammation. Interestingly, further 
evidence for a role of fractalkine – CX3CR1 
in mucosal immunity comes from infl am-
matory bowel disease studies. An elevated 
mucosal fractalkine expression and 
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 Figure 1  |  Potential involvement of fractalkine – CX3CR1 in IgA nephropathy-associated hematuria. Diagram based on the findings of 
Cox  et al. 6 Areas of uncertainty are indicated by black boxes. IgAN, IgA nephropathy; NK, natural killer; PBMC, peripheral blood mononuclear cell. 
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increased numbers of circulating and 
mucosal CX3CR1-expressing T cells have 
been detected in patients with active 
infl ammatory bowel disease. 10 
 Key questions regarding IgA nephro-
pathy-associated hematuria still need 
to be answered 
 Despite the beauty of the fi ndings of Cox 
 et al. , 6 there are still large black boxes 
( Figure 1 ) in our understanding of how 
IgAN-associated hematuria — in parti-
cular, macrohematuria — evolves: 
 What underlies the increased propen-
sity of PBMCs from IgAN to express 
CX3CR1 in response to lipopolysac-
charide? What is the origin of these 
cells — systemic or mucosal? 
 Which stimuli account for the increased 
CX3CR1 expression on PBMCs of 
macrohematuric IgAN patients  in vivo ? 
Are there diff erences between infection- 
and exercise-induced macro hematuria? 
 What accounts for the diff erence in 
uri nary fractalkine expression bet ween 
IgAN with and IgAN without macro-
hematuria episodes? Does urinary 
fractalkine indeed derive from injured 
glomeruli? For example, others have 
noted an increased fractalkine expres-
sion also in tubular epithelial cells. 11 
 If episodes of macroscopic hematuria in 
IgAN are indeed caused by glome rular 
•
•
•
•
infl ammation, possibly even glome r ular 
necroses, how specifi c is the involve-
ment of the CX3CR1 – fract alkine axis 
for this process? For example, fractalk-
ine is also over expressed in crescentic 
glomerulonephritis and renal allograft  
rejection, 11 and CX3CR1 is overex-
pressed in both conditions as well. 12 
However, these conditions are not typi-
cally associated with macrohematuria. 
 Th us, while the fi ndings of Cox  et al. 6 are 
stimulating our scientifi c minds, we feel 
we still need to go a long way before we get 
a grasp on why and how macrohematuria 
develops in IgAN. More insight may be 
derived from studying the CX3CR1 – frac-
talkine system in other clinical situations, 
such as in nephritic patients with active 
vasculitis, patients with postinfectious 
glomerulonephritis, IgAN patients with-
out microhematuria, and IgAN patients 
with acute mucosal infections and no 
macroscopic hematuria. More gene rally, 
a precise clinical characterization of IgAN 
subgroups will be a prerequisite for the in-
terpretation of studies aiming at the under-
standing of IgAN disease pathogenesis. 
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